Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Most Cited Paper
in Malaria Research and Control
18 Months Post-Publication
Class of 2026
“Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
RH5.1 · Matrix-M adjuvant · blood-stage malaria vaccine · Plasmodium falciparum · phase 1b trial · dose-escalation · age de-escalation · delayed-fractional third dose regimen · anti-RH5.1 serum IgG · growth inhibition activity · GIA · antibody avidity · RH5-specific T cell responses · malaria-endemic population · Tanzanian children · pre-erythrocytic vaccines · polyclonal IgG · non-human primate challenge model · Delayed third dose regimen · malaria pre-exposure
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Malaria Research and Control Papers, Class of 2026. https://pri.pepkio.com/top-papers/malaria-research-and-control/2026. Accessed 2026-07-23. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459